Perjeta
Roche’s subcutaneous Perjeta/Herceptin combo proves non-inferior to IV formulation in HER2-positive early breast cancer
December 12, 2019Research and Development Cancer, Herceptin, Perjeta, Roche, breast cancer, pharma
New Phase 3 data from Roche has shown that its subcutaneously-delivered formulation of Perjeta (pertuzumab) and Herceptin (trastuzumab), in combination …
Roche’s Perjeta secures NICE approval in adjuvant HER2+ metastatic breast cancer
February 15, 2019Medical Communications, Sales and Marketing NICE, Perjeta, Roche, pharma
NICE has announced its decision to authorise the use of Roche’s Perjeta (pertuzumab) on the NHS for the treatment of …
Scotland recommends Roche’s Perjeta for HER2+ metastatic breast cancer
January 15, 2019Manufacturing and Production, Sales and Marketing Breast cancer; Roche; Scotland, NHS, Perjeta, UK, pharma
Breast cancer patients in Scotland are set to receive an additional treatment option, as the Scottish Medicines Consortium announces its …
NICE turns down Roche’s Perjeta for post-surgery HER2-positive breast cancer
June 15, 2018Medical Communications, Sales and Marketing Cancer, NICE, Perjeta, Roche, breast cancer, pharma
Roche’s ongoing dispute with UK health service watchdog NICE over the availability of its monoclonal antibody Perjeta (pertuzumab) on the …
EMA’s CHMP backs Roche’s Perjeta combo in HER2-positive breast cancer
April 30, 2018Sales and Marketing Cancer, Herceptin, Perjeta, Roche, breast cancer, pharma
Roche’s Perjeta has edged one step closer to approval as a combo therapy after the EMA’s Committee for Medicinal Products …
NICE approves Perjeta for routine use on NHS
February 1, 2018Sales and Marketing Perjeta, Roche, biotech, drugs, pharma, pharmaceutical
NICE has given the nod to Roche’s Perjeta for routine first-line use, alongside Herceptin and chemotherapy, in patients with HER2-positive …
FDA grants breast cancer approval to Roche’s Perjeta/Herceptin combo therapy
December 21, 2017Sales and Marketing Cancer, FDA, Herceptin, Perjeta, Roche, breast cancer, pharma
Roche has announced that the FDA has granted approval to Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and a (Perjeta-based) …
NHS England seals access deals with big pharma for breast cancer and MS
November 9, 2017Sales and Marketing Cancer, Mavenclad, Merck, NHS, NHS England, NICE, Perjeta, Roche, Simon Stevens, breast cancer, multiple sclerosis
NHS England has entered into a commercial agreement with Merck which aims to provide access to innovative treatments for both …
FDA awards Roche priority review in HER2-positive breast cancer
October 2, 2017Sales and Marketing Cancer, FDA, Herceptin, Perjeta, Roche, breast cancer, pharma, pharmaceutical
Roche has revealed that its monoclonal antibody Perjeta (pertuzumab) has been awarded priority review by the FDA as an adjuvant …
Roche’s neoadjuvant breast cancer combo therapy shows strong Phase 3 results
March 2, 2017Research and Development Herceptin, Perjeta, Roche
Roche’s combination treatment of Perjeta (pertuzumab), Herceptin (trasdtuzumab) and chemotherapy met its primary endpoint in a recent Phase 3 study. …
NICE approves Roche’s Perjeta for breast cancer
November 16, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NICE, Perjeta, Roche, breast cancer
NICE has announced its approval of Roche’s Perjeta (pertuzumab) as a neoadjuvant treatment of HER2-positive, locally advanced, inflammatory or early-stage …
UK regulators do not back Roche’s breast cancer drug
May 20, 2016Medical Communications, Research and Development, Sales and Marketing NICE, Perjeta, Roche, breast cancer, recommendation
The National Institute for Health and Care Excellence (Nice) has provisionally turned down Swiss drugmaker Roche’s (VTX: ROG) breast cancer …
Roche oncology sales shine but profits dip
January 29, 2015Sales and Marketing Kadcyla, Perjeta, Roche, avastin, fourth quarter, oncology, q4
Roche has posted a mixed bag of financial results complemented only by strong growth in its oncology and immunology divisions. …
Roche dealt with two late-stage blows
December 19, 2014Sales and Marketing Alzheimer's, Alzheimer’s, Cancer, Kadcyla, Perjeta, Roche, Xeloda, trastuzumab emtansine
Swiss giant Roche’s breast cancer treatment Kadcyla has failed to meet its primary endpoint and its investigational Alzheimer’s treatment trial …
Global drug spending set to top $1 trillion
November 20, 2014Sales and Marketing Gilead, IMS, Kadcyla, Perjeta, drugs, hepatitis C, sovaldi, spend
Worldwide spending on drugs will reach over $1 trillion in 2014 and $1.3 trillion by 2018, according to a new …
